Cullinan Oncology LLC

NASDAQ CGEM

Data sourced from

and

Download Data

Cullinan Oncology LLC Invested Capital for the year ending December 31, 2023: USD 458.40 M

Cullinan Oncology LLC Invested Capital is USD 458.40 M for the year ending December 31, 2023, a -15.15% change year over year. Invested capital represents the total amount of capital invested in a company's operations, including both equity and debt. It is calculated by subtracting the sum of current liabilities (excluding short-term debt) from the total assets of a company. Invested capital reflects the long-term financial resources employed in the company's operations. It is an important measure to evaluate a company's capital structure and assess the amount of capital invested in its productive assets.

Cullinan Oncology LLC Invested Capital for the year ending December 31, 2022 was USD 540.22 M.

NASDAQ: CGEM

Cullinan Oncology LLC

CEO	Mr. Nadim Ahmed
IPO Date	Jan. 8, 2021
Location	United States
Headquarters	One Main Street, Cambridge, MA, United States, 02142
Employees	85
Sector	Healthcare
Industry	Biotechnology

Description

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Key trends